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This study was aimed to describe the outcomes of a
hypertension treatment programme in two outpatient
clinics in Cambodia. We determined proportions of
patients who met the optimal targets for blood pressure
(BP) control and assessed the evolution of mean systolic
and diastolic BP (SBP/DBP) over time. Multivariate
analyses were used to identify predictors of BP decrease
and risk factors for LTFU. A total of 2858 patients were
enrolled between March 2002 and June 2008 of whom
69.2% were female, 30.5% were aged X64years and
32.6% were diabetic. The median follow-up time was 600
days. By the end of 2008, 1642 (57.4%) were alive-in-care,
8 (0.3%) had died and 1208 (42.3%) were lost to follow-up.
On admission, mean SBP and DBP were 162 and
94mmHg, respectively. Among the patients treated,
a significant SBP reduction of 26.8mmHg (95% CI:
28.4–25.3) was observed at 6 months. Overall, 36.5% of
patients reached the BP targets at 24 months. The
number of young adults, non-overweight patients and
non-diabetics reaching the BP targets was more. Older
age (464 years), uncontrolled DBP (X90mmHg) on last
consultation and coming late for the last consultation
were associated with LTFU, whereas non-diabetic pa-
tients were 1.5 times more likely to default than diabetics
(95% CI: 1.3–1.7). Although the definite magnitude of the
BP decrease due to antihypertension medication over
time cannot be assessed definitely without a control
group, our results suggest that BP reduction can be
obtained with essential hypertension treatment in a
large-scale programme in a resource-limited setting.
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Introduction
In 2005, the World Health Organisation (WHO)
highlighted the importance of chronic diseases as a
neglected global health problem.
1 In most countries
the poorest people have the highest risk of develop-
ing chronic diseases and they are least able to
cope with the resulting financial consequences.
2
Recently, the burden of chronic diseases was
assessed in 23 selected low- and middle-income
countries, and it was shown that they were
responsible for 50% of the total disease burden in
2005. Moreover, the assessment showed that the
estimated death rates from chronic diseases in the
low- and middle-income countries were higher than
those in high-income countries.
3
Hypertension is one of the most common risk
factors for cardiovascular disease and has one of the
highest attributable risks for death, worldwide.
4,5
Hypertension control remains poor in most clinical
settings, despite the existence of several national and
international guidelines on diagnosis and manage-
ment.
6 For instance, in one study half of the patients
with hypertension in industrialized countries reported
receiving antihypertensive drugs, but only one-third of
them had their blood pressure (BP) controlled to the
recommended target of o140/90mmHg.
7 The situa-
tion is much worse in most developing countries
where BP control rates are often (but not always)
disappointingly low.
8–10 Unfortunately, the quality of
information from these contexts is weak as most
published studies are cross-sectional surveys and they
do not report treatment outcomes over time, nor do
they describe treatment programmes.
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www.nature.com/jhhIn Cambodia, recent surveys have shown an
unexpectedly high prevalence of arterial hyperten-
sion even in the relatively poor and traditional
rural communities.
11 The prevalence of hyperten-
sion was 12% in a rural community (Siem Reap) and
25% in a semi-urban community (Kampong Cham),
while access to care for this condition was and
still is almost non-existent in most public health
facilities.
In 2002 Me ´decins Sans Frontie `res Belgium, in
collaboration with the Cambodian Ministry of
Health, initiated a programme to provide care for
patients with hypertension and diabetes in two rural
settings, Siem Reap and Takeo provinces. The
similarities between the management of these
chronic conditions and HIV/AIDS led to the estab-
lishment of two Chronic Disease Clinics offering
care for HIV/AIDS, including antiretroviral treat-
ment, as well as care for diabetes and hypertension
and a few other chronic conditions (asthma, epi-
lepsy, arthritis and so on). This model of care
showed the feasibility of integrating care for
chronic diseases with that of HIV/AIDS and
resulted in excellent clinical and immunological
outcomes for the AIDS patients on antiretroviral
treatment and encouraging outcomes for diabetic
patients.
12,13 Nevertheless, the effectiveness of the
hypertension treatment programme has not been
fully assessed. This paper is unique in reporting the
results of treating hypertensive patients over time as
well as describing the model of care. The purpose of
this report is to describe the results and challenges
of a hypertension treatment programme in two rural
outpatient clinics in Cambodia.
Patients and methods
Setting
The hypertension care programme was initiated in
March 2002 in the Siem Reap province (population
700000) and one year later in the Takeo province
(population 800000) in Cambodia. Care was offered
on an outpatient clinic basis. The clinics were
located at the public referral hospitals and operated
similarly in both locations.
Study population
Adult patients diagnosed with hypertension
between March 2002 and June 2008 were enrolled
in the Takeo and Siem Reap Chronic Disease Clinics.
Only patients who returned at least once after
their first consultation were considered as having
‘enrolled’ in the programme and were included in
the study. Two BP measurements were taken at each
of these two first visits and were reported at
patients’ records, but only BP values at enrolment
(during the second visit) were considered as base-
line BP. Patient admissions were somewhat
restricted in 2007 due to high workload.
Programme description
We provided integrated patient-centred care for
hypertensive patients with and without diabetes,
in the same clinic that cared for HIV-positive
patients, as has already been described.
12 Patients
with hypertension were either self-referred or
referred by public or private health service providers.
The Chronic Disease Clinic staff included general
practitioners, nurses, drug educators, adherence coun-
sellors, a receptionist and support staff to facilitate
patient flow. All staff were trained in hypertension
and diabetes care. MSF subsidized care so that
patients were required to pay for initial registration
(one USD), for antihypertensive and diabetic drugs
until mid 2005 (at a subsidized price) and for
transportation. However, from mid 2005 onwards, all
drugs were free of charge. The programme never
covered transportation costs for patients.
Standardized care and follow-up procedures
The criteria for diagnosis of hypertension were
systolic BP (SBP) X140mmHg and/or diastolic BP
(DBP) X90mmHg on at least two occasions (two
separate visits). Patients diagnosed with hyperten-
sion by a qualified provider and on antihypertensive
treatment were also registered in the clinic. Patients
were seen first by a nurse and then, if control was
not achieved, by a medical doctor. During the first
consultation, history, physical examination and
management planning were recorded in an indivi-
dual patient file. Two BP measurements at first visit
and at all follow-up visits were performed after
patients rested for 5–10min and while lying on a
bed. BP readings were routinely made by nurses.
Medical doctors performed BP measurements only
on selected cases (uncontrolled BP, unexplained
fluctuation of BP) and always after the nurses’
readings. The second reading by the nurse (or a
third by a medical doctor if this was the case) was
routinely recorded. Manual mercury sphygmoman-
ometers were used in the clinics. Cuffs of two
different sizes were available to accommodate
differing arm circumferences. After late 2006 aner-
oid sphygmomanometers were also used to cope
with the heavier clinic workload. Verification of
these machines using mercury sphygmomanometers
was regularly performed by the clinic stuff.
Glucose levels were measured with a glucometer
(OneTouch; LifeScan Inc., Milpitas, CA, USA) using
capillary blood for all patients during the initial
consultation and upon clinical suspicion of diabetes
during follow-up visits. Systematic measurement of
glycated haemoglobin (HbA1c) for diabetic patients
at baseline and on a quarterly basis was performed
after May 2007 (high-performance liquid chromato-
graphy; Bio-Rad D-10, Hercules, CA, USA). For body
mass index (BMI) the WHO reference points for
Asian populations were used: 23–27.5kgm
 2 de-
fined as ‘overweight’ and 27.5kgm
 2 or above, as
‘obesity’.
14
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intake and appropriate diet was given to all patients
on an individual basis, by the doctors in the early
years of the programme (until 2005) and thereafter
by the counsellors. Patients without target organ
damage were under non-pharmacological care.
Patients with target organ damage were started
on mono-therapy and progressed to bi-therapy
and tri-therapy if BP target was not reached with
mono-therapy. The prescribed agents were generic
formulations of the following drug classes:
thiazide diuretics, b-blockers, angiotensin-convert-
ing enzyme inhibitors and Ca
þþblockers. BP targets
were o140/90mmHg for non-diabetic patients and
o130/80mmHg for diabetic patients.
For diabetic patients an oral hypoglycaemic agent
was administered: metformin if BMIX23kgm
 2 and
glibenclamide if BMIo23kgm
 2 or if contraindica-
tions to metformin. Two diabetes drugs were used
for patients failing to reach glucose control with
mono-therapy. Insulin therapy was only reserved for
patients with moderate-to-severe renal impairment.
Non-pharmacotherapy patients were followed up
on a bi-monthly basis. Patients on pharmacotherapy
were initially followed up bi-weekly, then every 1–3
months according to their WHO stage, existing
comorbidities and risk factors for cardiovascular
diseases. At each follow-up visit, BP, weight/BMI
and blood sugar were monitored for diabetic
patients; treatment acceptance, tolerance and ad-
herence were checked with open-ended questions;
and assessment for complications was performed.
Adherence to medication was self-reported. Due to
limited resources, we were not able to introduce an
electronic medication monitoring system that could
have provided more objective measurements of
adherence. If drug intake was irregular, patients
received counselling sessions and support from the
clinic’s nurse counsellors and drug educators.
Data collection
Clinical information was systematically recorded on
standardized clinical files designed specifically for
the programme. Information was prospectively
collected and entered into a software application
developed locally, specifically for chronic diseases.
Trained personnel extracted clinical, treatment and
laboratory data from individual patient records daily
and entered them into the database. A full-time data
manager routinely checked data entry for accuracy
and completeness.
Statistical analysis
Data from all adult patients diagnosed with hyper-
tension between March 2002 and June 2008, and
enrolled in the Takeo and Siem Reap Chronic
Disease Clinics were used in the analyses. Patients
had to have returned at least once after the first
consultation to be considered as having enrolled in
the programme. For the purposes of this analysis,
the date of enrolment of diabetic hypertensive
patients corresponded to the time when they were
diagnosed with hypertension, independently of
when this occurred during diabetes treatment.
Patient characteristics at admission and their
status at the end of the study period were summar-
ized using descriptive statistics. We assessed the
evolution of the mean SBP and DBP over treatment
time separately for non-diabetic and diabetic hyper-
tensive patients. Paired t-test was used to compare
baseline and subsequent paired values of BP.
To analyse the effect of various factors on BP
decrease over time, we performed a linear regression
on BP difference at month 12 of follow-up, sepa-
rately for SBP and DBP. The explanatory variables
included baseline BP, age group, sex and the time-
liness of last consultation, diabetes, BMI and type of
treatment.
A patient was defined as lost-to-follow-up if he/
she had missed a scheduled appointment by over 3
months and was not known to be dead or had not
transferred-out. Only patients who attended at least
two consultations were included in the analysis of
risk factors for loss to follow-up (LTFU). Potential
risk factors for LTFU, including sex, age, diabetes
comorbidity, year of admission, geographical origin,
last SBP and DBP, and last consultation (late or not
late), were assessed using a Cox regression model.
Data were analysed using Excel and STATA 8.2
(STATA Corp., College Station, TX, USA). The study
protocol was approved by the National Ethics
Committee for Health Research of Cambodia and
the Ethics Review Board of Me ´decins Sans Fron-
tie `res in January 2009.
Results
Patient characteristics
There were 2858 ambulatory patients diagnosed
with hypertension enrolled in the two clinics
between March 2002 and June 2008. The majority
of patients were self-referred and known to have
high BP. The characteristics of patients at first
consultation are shown in Table 1. Patients were
predominantly females (69.2%), and more than 60%
were X55 years old. On admission, mean SBP and
DBP were 162 and 94mmHg, respectively, while
91.2% of patients had elevated SBP and 76.7% had
elevated DBP. At the same time, 62% of the patients
were overweight and 22% were obese.
Of patients with type-II diabetes, 931 were
diagnosed with hypertension in the two clinics
and included in the analysis. Characteristics at first
consultation of diabetic patients with hypertension
were similar to those of non-diabetic patients with
hypertension (Table 1). The median first random
blood glucose measurement for diabetic patients
was 257mgdl and the median first glycated haemo-
globin was 11.4%.
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The median follow-up period per patient was 600
days. The follow-up time was longer for diabetic
patients than for non-diabetic patients (median 21
versus 19 months). Approximately 57 and 14% of
patients were prescribed two and three or more oral
antihypertensive drugs, respectively, at their last
consultation. The most commonly prescribed agents
were thiazide diuretics (1506), b-blockers (1283),
angiotensin-converting enzyme inhibitors (1083),
whereas Ca
þþ blockers (366) were prescribed
mostly during the last year of the programme.
Cohort outcomes
By the end of the observation period (December
2008), 1642 (57.5%) patients were alive and in care,
8 (0.3%) had died and 1208 (42.3%) were lost to
follow-up (Figure 1). Most LTFU (73.2%) occurred
within the first year after enrolment.
BP control
Overall, 36.5% of all patients and 49.3% of non-
diabetic hypertensive patients reached the BP target
at 24 months. Of the non-diabetic patients, 51.4% of
female patients and 58.9% of patients aged o55
years reached the BP target at 24 months. Only
12.3% of diabetic hypertensive patients reached
their BP target at 24 months.
Figure 2 illustrates the evolution of the mean SBP
and DBP values over treatment time. The initial
reduction observed during the first six months of
treatment was maintained over the 5-year period. t-
Test for paired values showed a significant decrease
in BP between first consultation and 6 months
(Po0.001) among diabetic and non-diabetic pa-
tients. The largest decrease was observed in non-
diabetic patients: an SBP decrease of 26.8mmHg
(95% confidence interval (CI): 28.4–25.3) between
first consultation and 6 months.
After adjusting for all factors, the multivariate
linear regression analysis showed a positive rela-
tionship between baseline SBP and SBP decrease at
month 12 and a negative relationship between age
group, BMI, diabetes and SBP decrease at month 12.
Decreased SBP after 12 months of treatment was
positively correlated to increased SBP at baseline,
younger age group, decreasing BMI and absence of
diabetes (Tables 2a and b). Sex, timeliness of last
consultation and number of antihypertensive drugs
Table 1 Characteristics of hypertensive patients enrolled in care
Hypertension only Diabetes with hypertension Total
Number of patients registered 1927 931 2858
Age in years, median (IQR) 58 (50–67) 57 (51–65) 58 (50–66)
Age group in years, n (%)
o35 1.6% 0.5% 1.3%
35–44 10.7% 8.3% 9.9%
45–54 26.0% 28.8% 26.9%
55–64 29.2% 36.1% 31.4%
464 32.5% 26.3% 30.5%
Women, n (%) 68.7% 70.3% 69.2%
Blood pressure
Systolic, mean (s.d.) 162 (25) 162 (18) 162 (23)
Diastolic, mean (s.d.) 93 (13) 95 (11) 94 (12)
% with systolic BP X140mmHg 88.2% 97.1% 91.2%
% with diastolic BP X90mmHg 72.2% 85.6% 76.7%
BMI (kg/m
2), median (IQR) 24.0 (21.2–27.0) 24.4 (21.9–27.0) 24.2 (21.5–27.0)
% overweight with BMI X23.0 60.5% 65.3% 62.3%
% obese with BMI X27.5 21.8% 21.8% 21.8%
Abbreviations: BMI: body mass index; BP, blood pressure; IQR, inter-quartile range.
The second BP readings during the second clinic visit were recorded as baseline SBP and DBP.
Patients diagnosed with
hypertension
N=2858
Died
N=8 (0.3%)
Lost to follow-
up
N=1208 (42.3%)
Lost to follow-up ≤1
year
N=884 (73.2%)
Lost to follow-up > 1
year
N=324 (26.8%)
Active on treatment
N=1642 (57.5%)
Figure 1 Flowchart of patients with hypertension diagnosed in
March 2002–June 2008 at the end of the study period.
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ship with SBP or DBP decrease at month 12.
Risk factors for LTFU
A total of 2778 hypertensive patients registered from
2002 to 2008 who had attended at least two clinic
consultations were included in the analysis of risk
factors for LTFU. All factors with a P-value o0.05 in
the univariate analysis were entered in the multi-
variate Cox regression model (Table 3). Older age
(464 years), uncontrolled DBP (X90mmHg) on last
consultation and coming late for the last consulta-
tion were significantly associated with LTFU.
Diabetes comorbidity was a significant protective
factor for retention in care. Patients without diabetes
were 1.5 times more likely to default than diabetes
patients (95% CI: 1.3–1.7).
Discussion
The treatment outcomes of this large cohort of
patients receiving standardized care in a resource-
limited setting with high prevalence of hypertension
are encouraging. However, these results should be
interpreted carefully as there was no control group
and the magnitude of the BP decrease due to
antihypertension medication cannot be definitely
assessed. Overall, significant decreases in BP were
observed in patients within 6 months of treatment
and lower BP levels were maintained throughout the
study period. However, the majority of patients did
not reach the recommended targets for optimal SBP
control. In light of the evidence that a decrease in BP
is associated with a decreased risk for cardiovascu-
lar disease and mortality in individuals with arterial
hypertension,
15–17 it is highly likely that patients
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Figure 2 Evolution of mean (s.d.) of BP in patients with
hypertension according to diabetes comorbidity. BP, blood
pressure.
Table 2a Univariate and multivariate linear regression analysis on SBP decrease after 12 months of treatment (n¼1260)
Explanatory variables Univariate analysis Multivariate analysis adjusting for all factors
Regression coefficient
(95% CI) P-value
Regression coefficient
(95% CI) P-value
Baseline systolic BP 0.99 (0.96 to 1.04) o0.001 1.00 (0.96 to 1.05) o0.001
Age group:  4.50 ( 6.86 to  2.15) o0.001  4.98 ( 6.68 to  3.27) o0.001
1: o45 years
2: 45–64 years
3: 464 years
Sex  1.45 ( 4.49 to 1.58) 0.347 0.52 ( 1.67 to 2.70) 0.642
0: male
1: female
Timeliness of last consultation:  3.39 ( 6.74 to  0.05) 0.047  0.93 ( 3.43 to 1.58) 0.468
1: on time
2: late
Diabetes:  9.38 (12.26 to  6.50) o0.001  7.64 ( 9.76 to  5.52) o0.001
0: no diabetes
1: diabetes
BMI  0.14 ( 0.38 to 0.10) 0.251  0.33 ( 0.54 to  0.13) 0.001
Number of BP drugs: 3.95 (1.88 to 6.02) o0.001  0.589 ( 2.00 to 0.83) 0.414
1 drug
2 drugs
3 drugs
4 drugs
Abbreviations: BMI: body mass index; BP, blood pressure; CI, confidence interval; SBP, systolic blood pressure.
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they did not reach their target. The fact that younger
patients (aged o55 years) responded better to
treatment is reassuring as the medical consequences
of uncontrolled hypertension in these individuals
are worse than those in the older age group.
Previous studies, in both high- and low-resource
countries, have shown that treatment targets for BP
are difficult to reach in clinical practice. Large
patient studies in industrialized countries have
found relatively low proportions (27–34%) of
hypertensive patients with fully controlled BP,
although a few surveys do show better results (48–
63%).
18–25 Quantitative data on BP control among
hypertensive patients treated in middle- and low-
income countries are more limited and certainly no
better (19.5–44.4%).
26–31 A recent systematic review
of the literature found no significant differences in
mean prevalence, awareness, treatment and control
of hypertension between developing and developed
countries.
10 However, a previous systematic review
of population-based studies on hypertension in sub-
Saharan Africa between 1975 and 2006 found that
among patients with previously diagnosed hyper-
tension, less than 30% were on drug treatment in
most studies, and less than 20% had their BP
controlled.
32 Both reviews identified a discoura-
gingly low number of scientific publications on
hypertension from resource-limited settings, and
published studies, other than cross-sectional sur-
veys, are more scarce.
33
Original studies on the association between
hypertension control and sex have been contra-
dictory. Several studies reported that men achieved
better control, others showed that female sex is a
predictor of treatment success and some found no
differences between the sexes.
34–38 In our study, no
significant differences of BP control between men
and women under treatment were found over time.
However, 70% of our patients were women and
this finding is consistent with a systematic review
that showed that in developing countries, overall,
women were more aware of their hypertension status
and more likely to get pharmacological treatment.
10
The reasons for less-than-optimal BP control
results are multi-factorial and include poor adher-
ence to taking medication, poor weight control, half-
hearted lifestyle modifications and lack of therapy
intensification. The latter could also be seen as a
combination of low aggressiveness in hypertension
management by clinicians and the difficulties in
introducing new classes of antihypertensive drugs,
which are either unavailable or unaffordable in
resource-limited settings. The issue of adherence to
treatment is central for long-term control of BP, but
often less than 50%, or even less than 30% of
patients, take their medication regularly.
39 In our
cohort, one-third of patients were diabetics and BP
control among them was worse when compared
with non-diabetic patients. Stricter treatment
targets for diabetic hypertensive patients (130/80
versus 140/90) may partly explain this difference.
Table 2b Univariate and multivariate linear regression analysis on DBP decrease after 12 months of treatment (n¼1260)
Explanatory variables Univariate analysis Multivariate analysis adjusting for all factors
Regression coefficient
(95% CI) P-value
Regression coefficient
(95% CI) P-value
Baseline diastolic BP 1.01 (0.97 to 1.05) o0.001 0.98 (0.92 to 1.03) o0.001
Age group: 1.61 (0.32 to 2.90) 0.014 1.18 (0.19 to 2.18) 0.1866994
1: o45 years
2: 45–64 years
3: 464 years
Sex:  1.50 ( 3.15 to 0.15) 0.075 0.79 ( 0.49 to 2.08) 0.225
0: male
1: female
Timeliness of last consultation:  2.56( 4.38 to  0.73) 0.006  0.82 ( 2.29 to 0.65) 0.272
1: on time
2: late
Diabetes:  3.79 ( 5.37 to  2.21) o0.001  3.57 ( 4.81 to  2.32) o0.001
0: no diabetes
1: diabetes
BMI 0.16 (0.03 to 0.29) 0.014  0.02 ( 0.14 to 0.10) 0.710
Number of antihypertensive drugs: 1.86 (0.74 to 2.99) 0.001 0.073 ( 0.75 to 0.90) 0.862
1 drug
2 drugs
3 drugs
4 drugs
Abbreviations: BMI: body mass index; BP, blood pressure; C, confidence interval; DBP, diastolic blood pressure.
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control can be difficult to achieve in diabetes.
17
A high proportion of our patients were overweight
or obese at first consultation. The weight control
results in our cohort were poor, especially for
diabetes (data not shown), and this could be, in
part, due to insufficient and inadequate patient
education. Lifestyle changes, implying behavioural
and environmental change, are known to be difficult
to promote effectively in a clinic setting. Moreover,
in our context we could not exclude a cultural
reluctance to lose weight, as there is no dietary
advice and no promotion of physical exercise at the
population level in the country.
In our settings we were seriously limited in
screening for and treatment of major complications
related to hypertension, especially cardiovascular
disease. Lack of experienced physicians and lack of
access to appropriate diagnostics may have resulted
in serious gaps in diagnosing such complications.
Limited financial resources also prevented us from
systematically introducing lipid-lowering agents in
our protocols, as these drugs remained prohibitively
expensive and not widely available in Cambodia.
The high LTFU observed among patients with
hypertension strikingly contrasts with the low LTFU
documented among HIV/AIDS patients on antire-
troviral treatment treated at the same clinic (cumu-
lative LTFU of 3% over 5 years). One contributing
factor could be the inequality in care: HIV/AIDS
patients received free health care, money for
transportation, food and social support, whereas
hypertensive patients did not get any of these
benefits.
40,41 In our cohort, patients 64 years or
older, patients late for their last appointment and
those with poor SBP control during their last visit
were more likely to be lost to follow-up. Older
patients are unlikely to work and depend on family
members for living and health expenditures, such as
transport and drugs, over which they have no
Table 3 Univariate and multivariate Cox regression analysis of risk factors for LTFU among all hypertensive patients
a (n¼2778)
Factors No. lost to follow-up/
follow-up time
HR 95% CI P-value aHR
b 95% CI P-value
Sex
Male 23.4% 1 1
Female 19.9% 0.85 0.75–0.96 0.0076 0.99 0.88–1.12 0.902
Age (years)
p64 16.6% 1 1
464 34.2% 2.06 1.84–2.31 o0.001 1.78 1.58–2.01 o0.001
Diabetes
Yes 16.1% 1 1
No 23.8% 1.48 1.30–1.67 o0.001 1.51 1.33–1.71 o0.001
Origin
Inside province 21.8% 1 0.98–1.66
Outside province 27.8% 1.28 0.065
Treatment centre
Siem Reap 20.2% 1 1
Takeo 23.0% 1.14 1.00–1.29 0.0399 1.09 0.96–1.25 0.186
Year of admission
2002 18.1% 1 1
2003–2008 20.9% 1.08
c 1.04–1.12 0.002 0.97 0.93–1.01 0.147
Last SBP (mmHg)
o140 16.2% 1 1
X140 24.5% 1.51 1.34–1.70 o0.001 1.11 0.97–1.28 0.129
Last DBP (mmHg)
o90 16.3% 1 1
X90 32.9% 2.02 1.80–2.27 o0.001 1.78 1.56–2.05 o0.001
Timeliness of last consultation
On time 15.5% 1 1
Late 42.1% 2.71 2.42–3.04 o0.001 2.24 1.99–2.53 o0.001
Abbreviations: aHR, adjusted hazards ratio; CI, confidence interval; DBP, diastolic blood pressure; HR, hazards ratio; LTFU, loss to follow-up;
SBP, systolic blood pressure.
aIncluded all patients registered between March 2002 and June 2008, and attended at least two consultations.
bAll factors with P-value o0.05 in univariate analysis were included in the multivariable regression model. P-value for the likelihood ratio test for
the model was o0.001.
cScore test for trend of rates with an estimate of rate ratio for a one unit increase in year.
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contrary to HIV patients, have several alternatives
for care such as traditional medicine and local
pharmacies. Antihypertensive medicines similar to
the ones provided by the clinics can be bought at
local pharmacies thereby saving travel costs and
time. Finally, the weakness of the counselling and
patient education components of care probably led
to an insufficient understanding by patients of the
disease and its consequences if untreated, leading to
reduced motivation to continue treatment.
This study had certain limitations. First, even
though data were collected on standardized patient
forms and entered prospectively into a specifically
designed software programme, errors or omissions
could have occurred, as data were collected from a
routine clinic and not specifically for research
purposes. Second, we acknowledge that we only
used biological measurements, as surrogate markers,
for hypertension treatment outcomes. The lack of
access to specialized diagnostics and care for
complications and lack of standardized case defini-
tions prevented us from collecting information
about them, as mentioned above. Third, deaths
were likely underestimated in our cohort and
misclassified as LTFU, as we had no means of
checking on defaulters. Fourth, we acknowledge
that regression to the mean and habituation to
repeated BP measurements could have had an
effect on the decrease in BP observed during
follow-up.
42 Without control cases the specific effect
of antihypertensive treatment cannot be fully
assessed. Despite these limitations, our study’s
strengths were its large size, relatively lengthy
follow up, prospective data collection and use of
specialized software.
In conclusion, the findings of this study suggest
that improvement in BP control can be obtained in
individuals with essential hypertension treated in a
low-resource setting. Although the exact magnitude
of the BP decrease due to antihypertension medica-
tion over time cannot be definitely assessed without
a control group, our results do offer encouragement
for scaling up care for chronic diseases like
hypertension, as they are a large and growing
burden of illness in the developing countries.
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